CAR-T Funding: It's (Nearly) All About The Price In The UK
Executive Summary
Gilead’s Yescarta and Novartis’s Kymriah are pioneering and effective approaches to the treatment of serious cancers, but in the UK they have had mixed fortunes at the hands of NICE, the body that decides whether new therapies are value for money and should be available under the national health service. Both companies will probably have to cut their asking price to secure routine funding
You may also be interested in...
Payment For Outcomes Key To EU Market Access for Yescarta
Payment for outcomes has played an important role in enabling Gilead to secure reimbursement for Yescarta in some EU markets. It is likely to be the key focus for the company as it works to expand patient access to the potentially transformative CAR-T therapy across Europe.
UK: Funding For Second Kymriah Indication After Talks And Price Cut
UK HTA body NICE says a second indication for Novartis’s groundbreaking CAR-T cell therapy Kymriah should be covered under the Cancer Drugs Fund.
NICE Explains Its UK Funding Recommendation For Kymriah
The final appraisal document published today by the health technology assessment body NICE provides more insight into the health technology assessment body’s recent recommendation on